Atlas Trials

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria

Clinical trial NCT04513548 · TERMINATED

Trial details

NCT number
NCT04513548
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Spontaneous UrticariaCholinergic UrticariaCold Urticaria
Start date
2020-08-05
Primary completion
2022-07-19
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.